Two Sigma Advisers’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-4,275
Closed -$70.3K 2387
2025
Q2
$70.3K Buy
4,275
+365
+9% +$6.3K ﹤0.01% 2233
2025
Q1
$71.2K Buy
3,910
+220
+6% +$6.28K ﹤0.01% 2282
2024
Q4
$137K Buy
3,690
+1,130
+44% +$43.2K ﹤0.01% 2178
2024
Q3
$81.9K Sell
2,560
-7,930
-76% -$440K ﹤0.01% 2183
2024
Q2
$861K Buy
10,490
+1,050
+11% +$114K ﹤0.01% 1630
2024
Q1
$1.37M Buy
9,440
+4,630
+96% +$391K ﹤0.01% 1420
2023
Q4
$443K Sell
4,810
-1,230
-20% -$125K ﹤0.01% 1967
2023
Q3
$997K Sell
6,040
-15,650
-72% -$2.03M ﹤0.01% 1523
2023
Q2
$1.37M Sell
21,690
-42,270
-66% -$2.56M ﹤0.01% 1401
2023
Q1
$2.17M Sell
63,960
-820
-1% -$42.8K 0.01% 1235
2022
Q4
$3.74M Buy
64,780
+18,820
+41% +$1.16M 0.01% 902
2022
Q3
$4.32M Buy
45,960
+39,950
+665% +$5.69M 0.01% 804
2022
Q2
$1.34M Buy
+6,010
New +$2.01M ﹤0.01% 1442
2022
Q1
Sell
-1,860
Closed -$1.23M 2755
2021
Q4
$1.23M Buy
+1,860
New +$1.42M ﹤0.01% 1455
2020
Q3
Sell
-490
Closed -$343K 2421
2020
Q2
$343K Sell
490
-3,400
-87% -$1.96M ﹤0.01% 2060
2020
Q1
$1.36M Buy
3,890
+240
+7% +$170K 0.01% 1310
2019
Q4
$2.29M Buy
+3,650
New +$1.78M 0.01% 1161

Other funds holding CDLX

Two Sigma Advisers's CDLX Position: Q3 2025 in Review

Two Sigma Advisers sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 4,275 shares — an estimated $70.3K sold.

Two Sigma Advisers first reported a position in CDLX in Q4 2019 and held it in 17 quarters. The position peaked at $4.32M in Q3 2022. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • Two Sigma Advisers reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 4,275 Cardlytics shares in Q3 2025, an estimated $70.3K.
  • Two Sigma Advisers first reported a position in Cardlytics in Q4 2019 and held it in 17 quarters.
  • Two Sigma Advisers's Cardlytics position peaked at $4.32M in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.